Sign In
Register
eISSN:2278-5299

International Journal of Latest Research in Science and Technology

DOI:10.29111/ijlrst   ISRA Impact Factor:3.35,  Peer-reviewed, Open-access Journal

A News Letter Sign UP!
GASTRIC CANCER AND PERSPECTIVE VIEW OF HER2 BIOMARKER

Research Paper Open Access

International Journal of Latest Research in Science and Technology Vol.5 Issue 2, pp 5-9,Year 2016

GASTRIC CANCER AND PERSPECTIVE VIEW OF HER2 BIOMARKER

Dr. Ganesh Adhikari

Correspondence should be addressed to :

Received : 02 March 2016; Accepted : 04 April 2016 ; Published : 30 April 2016

Share
Download 125
View 179
Article No. 10630
Abstract

The advent of human epidermal growth factor receptor-2 (HER2) Status and biomarker testing has modified the treatment and prognosis of gastric, breast and colorectal cancer. Epidermal growth factor receptor and HER-2 family maneuvers a key role in the exploitation of gastric cancer by detecting the epidermis express in gastric cancer tissue and to investigate serum and tissue HER2. Targeted drugs i.e. antineoplastic therapies such as EGFR tyrosine kinase inhibitors have application in the treatment of gastric cancer. OBJECTIVES: To scrutinize the manifestation of HER2 in gastric cancer and assess their association with clinic-pathological hallmarks: the tumorigenesis and the metastasis of gastric tumor. METHODS: 1. Analysis of a prospective database with 68 patients for gastric cancer in the first affiliated hospital of Anhui Medical University range from 2013.4-2014.3 Immunohistochemistry staining(IHC) was used to detect the expression of tissue HER2 in 68 cases of gastric cancer and adjacent non-cancer tissue and 40 cases of adjacent normal EGFR and HER2. Preoperative serum samples were extracted from 68 gastric tumor patients and 40 healthy volunteers. Serum and tissue of HER2 were determined using an enzyme-linked immunosorbent assay (ELISA). 2. To analysis the relationship of clinic pathological features with the expressions HER2 and the correlation of diagnosis and prognosis with gastric cancer. 3.All data were processed by SPPSS.13.0 Results: There was significant difference between the overexpression of Her2 in gastric cancer and the low expression in adjacent non-cancer tissue and adjacent normal epithelial tissue（P＜0.01. Serum Her2 were significantly higher in patients with gastric cancer than those in normal control group（P＜0.01）. The Her2 levels have no relationship to sex, age, tumor location and histological grades（P＞0.05）, but had significantly statistic difference between lymph node metastasis, Histological differentiation and Dukes stage（P＜0.01). CONCLUSION: The overexpression of Her2 in gastric cancer apprise that the HER2 may maneuver an important role in progression of gastric cancer; serum HER2 can be used as a new tumor marker to esteem the procession of gastric cancer.

Key Words   
Gastric Cancer, GF (growth factor), CEA (carcino-embriyogenic antigen) Human Epidermal Growth Recept

Copyright
References
  1. Carlos Gomez-Martín, Fernando Lopez-Rios: A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond Cancer Letters 351 (2014) 30–40
  2. Jemal A, Center MM, Desantis C, Global patterns of cancer incidence and mortality rates and trends 2010 Aug;19(8):1893-907
  3. Jeng-Yih Wu , Affiliations: Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Department of Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan ⨯ Chun-Chia Cheng , Affiliation: Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, Taiwan ⨯ Jaw-Yuan Wang  Discovery of Tumor Markers for Gastric Cancer by Proteomics January 3, 2014 DOI: 10.1371
  4. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991; 265:1287–1289
  5. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002; 11:235–25
  6. Cui DX Zhang I, Yan XJ, Zhang LX, a microarray-based gastric carcinoma prewarning system. World Journal of Gastroenterology 11:1273-1282,2005
  7. Barry Dent, S. Michael Griffin, Gastric tumors 608-012;2014
  8. Oliver Stoss, PhD, Martina Schmitt, PhD, Dirk Zielinski, PhD, HER2 Diagnostics in Gastric Cancer 2010;34-38.
  9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783–92.
  10. Olayioye, M.A., Neve, R.M., Lane, H.A The ErbB signaling network: receptor heterodimerization in development and cancer.2010;19;3159-67
  11. Parisa Karimi, Farhad Islami, Sharmila Anandasabapathy, Gastric Cancer: Descriptive Epidemiology, Risk Factors, March 11, 2014; DOI: 10.1158/1055-9965.EPI-13-1057.
  12. Parisa Karimi, Farhad Islami, Sharmila Anandasabapathy Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention. March 11, 2014; DOI: 10.1158/1055-9965.EPI-13-1057
  13. Howlader N, Noone A, Krapcho M, SEER cancer statistics review, 1975–2008. Bethesda, MD: National Cancer Institute 2011;19
  14. (Narikazu Boku, HER2-positive gastric cancer, Gastric Cancer (2014) 17:1–12)
  15. Freedman N, Derakhshan M, Abnet C, Male predominance of upper gastrointestinal adenocarcinoma cannot be explained by differences in tobacco smoking in men versus women. Eur J Cancer 2010; 46:2473–8.
  16. George Peros, Theodore Liakakos, Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology; World J Gastroenterol 2012 January 14; 18(2): 150-155
  17. Duffey B, Monga M. Principles of endoscopy. In: Wein AJ, Kavoussi LR, Novick AC, et al, eds. Campbell-Walsh Urology. 10th ed. Philadelphia, PA: Elsevier Saunders; 2012: chap 8
  18. Yang L. Incidence and mortality of gastric cancer in China, World J Gastroenterol. 2006;12(1):17–20.
  19. A. Ramos-vara, M.A. Miller When Tissue Antigens and Antibodies Get Along Revisiting the Technical Aspects of Immunohistochemistry—The Red, Brown, and Blue Technique Pathology 51 (1): 42–87. Retrieved 13 February 2014.
  20. Tsigris C, Tsigris C, Karayiannakis A J, Zbar A, et al. Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer[J]. Cancer Lett, 2002, 184(2): 215-222
  21. Krainer M, Brodowicz T, Zeillinger R, et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer[J]. Oncology, 1997, 54(6): 475-481.
To cite this article

Dr. Ganesh Adhikari , " Gastric Cancer And Perspective View Of Her2 Biomarker ", International Journal of Latest Research in Science and Technology . Vol. 5, Issue 2, pp 5-9 , 2016

Responsive image

MNK Publication was founded in 2012 to upholder revolutionary ideas that would advance the research and practice of business and management. Today, we comply with to advance fresh thinking in latest scientific fields where we think we can make a real difference and growth now also including medical and social care, education,management and engineering.

Responsive image

We offers several opportunities for partnership and tie-up with individual, corporate and organizational level. We are working on the open access platform. Editors, authors, readers, librarians and conference organizer can work together. We are giving open opportunities to all. Our team is always willing to work and collaborate to promote open access publication.

Responsive image

Our Journals provide one of the strongest International open access platform for research communities. Our conference proceeding services provide conference organizers a privileged platform for publishing extended conference papers as journal publications. It is deliberated to disseminate scientific research and to establish long term International collaborations and partnerships with academic communities and conference organizers.